Due to health issues, this site is no longer maintained and will be shut down shortly.


Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies. The company develops vaccines for the treatment cancer and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of melanoma, lung, head and neck, renal, and bladder; and VB10.16, a therapeutic DNA vaccine for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer. The company has clinical collaboration agreements with Roche and Nektar Therapeutics. The company was formerly known as Vaccibody AS. Nykode Therapeutics AS was founded in 2007 and is based in Oslo, Norway.

26.46 NOK
As of 03/08/2023

Security Information
Category1:  Global Equity
Category2:  Comon stocks
Category3:  Developed markets ex-US
GICS sector:  Health Care
Index country:  Norway
Country of incorporation:  
IPO date:  12/13/2021
Stock exchange:    Oslo Bors Asa
Exchange country:   Norway
Market cap:   10,152,415,232 NOK
Current dividend yield:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy